Refractory Angina Market Expected to Gain Momentum Through 2034, According to DelveInsight

DelveInsight's "Refractory Angina Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Refractory Angina, offering comprehensive insights into the Refractory Angina revenue trends, prevalence, and treatment landscape. The report delves into key Refractory Angina statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Refractory Angina therapies. Additionally, we cover the landscape of Refractory Angina clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Refractory Angina treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Refractory Angina space.

To Know in detail about the Refractory Angina market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Refractory Angina Market Forecast
https://www.delveinsight.com/sample-request/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Refractory Angina Market Report:
• The Refractory Angina market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In July 2025, XyloCor Therapeutics has initiated dosing of the first patient in the multicenter, randomized Phase IIb EXACT-2 trial to evaluate its gene therapy candidate XC001 (encoberminogene rezmadenovec) for coronary artery disease and refractory angina. The procedure, performed by Timothy Henry at The Christ Hospital Health Network in Cincinnati, Ohio, marks a key milestone in XC001's development. The double-blind study will enroll 100 patients with refractory angina to assess the safety and efficacy of the therapy, delivered directly into the heart muscle using SmartWise's Extroducer Infusion Catheter System. This builds on positive outcomes from the earlier Phase I/II EXACT-1 trial.
• In January 2025, XyloCor Therapeutics, Inc. ("XyloCor"), a clinical-stage biopharmaceutical company developing innovative gene therapies for cardiovascular disease, has announced the successful completion of a $67.5 million Series B financing. The new funding will support a randomized, double-blind Phase 2b clinical trial (EXACT-2) evaluating XC001 (encoberminogene rezmadenovec) for refractory angina, utilizing a novel non-surgical endocardial injection method. Additionally, the financing will fund another randomized, double-blind Phase 2 trial investigating XC001 as an adjunctive therapy for coronary artery bypass graft (CABG) surgery. XC001 represents a promising therapeutic approach for chronic and debilitating cardiovascular conditions affecting over one million individuals in the U.S. who currently lack viable treatment options.
• In July 2024, XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative gene therapies for cardiovascular diseases, has entered into a licensing agreement with SmartWise, a division of SmartCella Holding AB. Under the agreement, XyloCor gains rights to the Extroducer® Infusion Catheter System®, a pioneering endovascular device designed to deliver advanced therapies directly into the heart and other hard-to-reach tissues. XyloCor plans to use the Extroducer for catheter-based endocardial delivery of its lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in upcoming clinical trials and for commercial purposes. The Extroducer offers a more efficient method for administering gene therapy to patients with refractory angina.
• Key Refractory Angina Companies: Gene Biotherapeutics, XyloCor Therapeutics, Centocor, Inc., Lisata Therapeutics, and others
• Key Refractory Angina Therapies: Generx (Ad5FGF-4), XC001, AdVEGFXC1, Abciximab, CLBS14 (low-dose), and others
• The Refractory Angina market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Refractory Angina pipeline products will significantly revolutionize the Refractory Angina market dynamics.
• The analysis shows that the overall prevalence of angina in adults aged 20 and older is 4%, equating to about 8 million people in the United States.
• The analysis reveals that the prevalence of angina differs significantly across populations, ranging from 0.73% to 14.4% (with a population-weighted mean of 6.7%) in women, and from 0.76% to 15.1% (with a population-weighted mean of 5.7%) in men. The prevalence is found to be closely correlated between the sexes within populations.
• Our analysis estimates that approximately 300,000 to 900,000 patients in the United States suffer from refractory angina, with 25,000 to 75,000 new cases diagnosed annually.
• According to the analysis, nearly 2.3 million people in the UK are affected by some form of coronary artery disease.
• The analysis estimates that the prevalence of refractory angina pectoris ranges from 5% to 10% in stable CAD patients, potentially resulting in 50,000 to 100,000 new cases per year in the United States and 30,000 to 50,000 new cases annually in Europe.

Refractory Angina Overview
Refractory angina is a chronic condition characterized by persistent chest pain despite optimal treatment for coronary artery disease (CAD). It occurs when the heart's demand for oxygen exceeds the supply, even though patients are on medication or have undergone procedures like angioplasty. This form of angina is often difficult to manage and can significantly impact a person's quality of life. Treatment options focus on symptom management, including pain relief and improving blood flow, and may involve medications, lifestyle changes, or interventions like nerve stimulation or surgical procedures.

Get a Free sample for the Refractory Angina Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Refractory Angina Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Refractory Angina Epidemiology Segmentation:
The Refractory Angina market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Refractory Angina
• Prevalent Cases of Refractory Angina by severity
• Gender-specific Prevalence of Refractory Angina
• Diagnosed Cases of Episodic and Chronic Refractory Angina

Download the report to understand which factors are driving Refractory Angina epidemiology trends @ Refractory Angina Epidemiology Forecast
https://www.delveinsight.com/sample-request/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Refractory Angina Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Refractory Angina market or expected to get launched during the study period. The analysis covers Refractory Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Refractory Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Refractory Angina Therapies and Key Companies
• Generx (Ad5FGF-4): Gene Biotherapeutics
• XC001: XyloCor Therapeutics
• AdVEGFXC1: XyloCor Therapeutics
• Abciximab: Centocor, Inc.
• CLBS14 (low-dose): Lisata Therapeutics

Discover more about therapies set to grab major Refractory Angina market share @ Refractory Angina Treatment Landscape
https://www.delveinsight.com/sample-request/refractory-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Refractory Angina Market Drivers
• Unmet medical needs
• Rising prevalence of coronary artery disease (CAD)
• Advancements in treatment options
• Improved awareness and diagnosis
• Aging population

Refractory Angina Market Barriers
• Limited treatment options
• High treatment costs
• Regulatory hurdles
• Uncertain reimbursement policies
• Complexity in disease management

Scope of the Refractory Angina Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Refractory Angina Companies: Gene Biotherapeutics, XyloCor Therapeutics, Centocor, Inc., Lisata Therapeutics, and others
• Key Refractory Angina Therapies: Generx (Ad5FGF-4), XC001, AdVEGFXC1, Abciximab, CLBS14 (low-dose), and others
• Refractory Angina Therapeutic Assessment: Refractory Angina current marketed and Refractory Angina emerging therapies
• Refractory Angina Market Dynamics: Refractory Angina market drivers and Refractory Angina market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Refractory Angina Unmet Needs, KOL's views, Analyst's views, Refractory Angina Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.